Table 1.
FDA approvals for poly(ADP‐ribose) polymerase inhibitors in all cancers
| Disease and drug | Treatment | Approval date |
|---|---|---|
| Ovarian cancer | ||
| Olaparib | Advanced ovarian cancer | 12/19/2014 |
| Ovarian cancer maintenance therapy | 08/17/2017 | |
| First‐line maintenance therapy in BRCA‐mutated advanced ovarian cancer | 12/19/2018 | |
| First‐line maintenance therapy with bevacizumab for HRD‐positive advanced ovarian cancer | 05/08/2020 | |
| Rucaparib | Advanced ovarian cancer | 12/19/2016 |
| Maintenance therapy of recurrent ovarian cancer | 09/16/2018 | |
| Niraparib | Recurrent ovarian cancer | 03/27/2017 |
| Late‐line treatment of recurrent ovarian cancer | 10/23/2019 | |
| First‐line monotherapy for platinum‐responsive advanced ovarian cancer regardless of biomarker status | 04/29/2020 | |
| Breast cancer | ||
| Olaparib | Germline BRCA‐mutated metastatic breast cancer | 01/12/2018 |
| Talazoparib | Germline BRCA‐mutated HER2‐negative locally advanced or metastatic breast cancer | 10/16/2018 |
| Pancreatic cancer | ||
| Olaparib | First‐line maintenance therapy in BRCA‐mutated metastatic pancreatic cancer | 12/30/2019 |
| Prostate cancer | ||
| Rucaparib | Monotherapy for BRCA1/2 mutant mCRPC | 05/15/2020 |
| Olaparib | HR repair gene mutated mCRPC | 05/20/2020 |
Abbreviations: FDA, U.S. Food and Drug Administration; HR, homologous recombination; HRD, homologous recombination deficient mCRPC, metastatic castration‐resistant prostate cancer.